Genetic susceptibility to adverse drug reactions

被引:209
作者
Pirmohamed, M [1 ]
Park, BK [1 ]
机构
[1] Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GE, Merseyside, England
关键词
D O I
10.1016/S0165-6147(00)01717-X
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Adverse drug reactions (ADRs) are a major clinical problem. Genetic factors can determine individual susceptibility to both dose-dependent and dose-independent ADRs. Determinants of susceptibility include kinetic factors, such as gene polymorphisms in cytochrome P450 enzymes, and dynamic factors, such as polymorphisms in drug targets. The relative importance of these factors will depend on the nature of the ADR; however, it is likely that more then one gene will be involved in most instances. In the future, whole genome single nucleotide polymorphism (SNP) profiling might allow an unbiased method of determining genetic predisposing factors for ADRs, but might be limited by the lack of adequate numbers of patient samples. The overall clinical utility of genotyping in preventing ADRs needs to be proven by the use of prospective randomized controlled clinical trials.
引用
收藏
页码:298 / 305
页数:8
相关论文
共 88 条
  • [1] MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia
    Abbott, GW
    Sesti, F
    Splawski, I
    Buck, ME
    Lehmann, WH
    Timothy, KW
    Keating, MT
    Goldstein, SAN
    [J]. CELL, 1999, 97 (02) : 175 - 187
  • [2] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
    Aithal, GP
    Day, CP
    Kesteven, PJL
    Daly, AK
    [J]. LANCET, 1999, 353 (9154) : 717 - 719
  • [3] Ando Y, 2000, CANCER RES, V60, P6921
  • [4] A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene:: association with tardive dyskinesia in schizophrenia
    Basile, VS
    Özdemir, V
    Masellis, M
    Walker, ML
    Heltzer, HY
    Lieberman, JA
    Potkin, SG
    Alva, G
    Kalow, W
    Macciardi, FM
    Kennedy, JL
    [J]. MOLECULAR PSYCHIATRY, 2000, 5 (04) : 410 - 417
  • [5] Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia
    Basile, VS
    Masellis, M
    Badri, F
    Paterson, AD
    Meltzer, HY
    Lieberman, JA
    Potkin, SG
    Macciardi, F
    Kennedy, JL
    [J]. NEUROPSYCHOPHARMACOLOGY, 1999, 21 (01) : 17 - 27
  • [6] INCIDENCE OF ADVERSE DRUG EVENTS AND POTENTIAL ADVERSE DRUG EVENTS - IMPLICATIONS FOR PREVENTION
    BATES, DW
    CULLEN, DJ
    LAIRD, N
    PETERSEN, LA
    SMALL, SD
    SERVI, D
    LAFFEL, G
    SWEITZER, BJ
    SHEA, BF
    HALLISEY, R
    VANDERVLIET, M
    NEMESKAL, R
    LEAPE, LL
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (01): : 29 - 34
  • [7] The costs of adverse drug events in hospitalized patients
    Bates, DW
    Spell, N
    Cullen, DJ
    Burdick, E
    Laird, N
    Petersen, LA
    Small, SD
    Sweitzer, BJ
    Leape, LL
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (04): : 307 - 311
  • [8] BEUTLER E, 1991, NEW ENGL J MED, V324, P169
  • [9] Testing drug response in the presence of genetic information: sampling issues for clinical trials
    Cardon, LR
    Idury, RM
    Harris, TJR
    Witte, JS
    Elston, RC
    [J]. PHARMACOGENETICS, 2000, 10 (06): : 503 - 510
  • [10] Extension of a pilot study: Impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness
    Chou, WH
    Yan, FX
    de Leon, J
    Barnhill, J
    Rogers, T
    Cronin, M
    Pho, M
    Xiao, V
    Ryder, TB
    Liu, WW
    Teiling, C
    Wedlund, PJ
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2000, 20 (02) : 246 - 251